Importantly, prolonged intervention of anti-PD-L1, not anti-PD-1, resulted in increase of therapeutic effectiveness of PLK1122DC_TriVax where complete tumour rejections were observed (Fig. S5). The gene discussed is CD274; the disease is neoplasm.